ResultsIQ

ResultsIQ › Latest results › NGL Fine-Chem Limited

NGL Fine-Chem Limited Q4 FY26 earnings call summary

NSE: NGLFINE · BSE: 524774

Earnings call of 25 May 2026, summarised by AI from the filing.

NGL Fine-Chem Q4 FY26 revenue ₹149.23 cr (+57% YoY), EBITDA margin 14.35%; Phase II commissioning delayed to early Q2 FY27.

Key takeaways

  1. Change Phase II commissioning delayed to early Q2 FY27 from Q1 FY27 due to gas and labour shortages.
  2. Driver Higher volumes across portfolio and geographies, supported by improved capacity utilization and partial price pass-through.
  3. Risk Geopolitical developments increased freight and raw material costs; fixed-price contracts limited immediate pass-through.

Original filing on BSE

NGL Fine-Chem Limited Q1 FY27 results

As filed: Revenue ₹139 cr (+34% year on year), EBITDA ₹23.3 cr (+112% year on year), PAT ₹18.4 cr (+104% year on year), EBITDA margin 16.7% (+616 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹149 cr (+57% year on year), EBITDA ₹21.4 cr (+257% year on year), PAT ₹13.5 cr (+300% year on year), EBITDA margin 14.4% (+803 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 803 bps year on year. Profit fell 14% from last quarter. Share price after the results: +22.1% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹128 cr (+43% year on year), EBITDA ₹22.3 cr (+300% year on year), PAT ₹15.7 cr (+300% year on year), EBITDA margin 17.5% (+1,000 bps). Score 94 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Share price after the results: +29.6% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹120 cr (+29% year on year), EBITDA ₹17.0 cr (+55% year on year), PAT ₹10.0 cr (0% year on year), EBITDA margin 14.2% (+234 bps). Score 75 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 234 bps year on year. Revenue rose ₹27.0 cr on a year ago, more than the ₹13.0 cr it added the year before. Share price after the results: −8.1% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹104 cr (+14% year on year), EBITDA ₹11.0 cr (+22% year on year), PAT ₹9.0 cr (0% year on year), EBITDA margin 10.6% (+69 bps). Score 56 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was above it. EBITDA margin rose 69 bps year on year. Other income 50% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +8.4% in 28 days (Nifty 500: −0.9%).
  • Q4 FY25: Revenue ₹95.0 cr (−5% year on year), EBITDA ₹6.0 cr (−60% year on year), PAT ₹1.0 cr (−92% year on year), EBITDA margin 6.3% (−868 bps). Score 13 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 868 bps year on year. Tax rate 0%. Share price after the results: −22.2% in 29 days (Nifty 500: +2.0%).
  • Q3 FY25: Revenue ₹89.0 cr (+1% year on year), EBITDA ₹5.0 cr (−62% year on year), PAT ₹1.0 cr (−90% year on year), EBITDA margin 5.6% (−915 bps). Score 5 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 915 bps year on year. Tax rate 0%. Revenue fell 4% from last quarter. Revenue rose ₹1.0 cr on a year ago, against ₹16.0 cr the year before.
  • Q2 FY25: Revenue ₹93.0 cr (+16% year on year), EBITDA ₹11.0 cr (−21% year on year), PAT ₹10.0 cr (0% year on year), EBITDA margin 11.8% (−567 bps). Score 25 of 100, Below trend. EBITDA margin fell 567 bps year on year. Other income 38% of PBT. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

NGL Fine-Chem Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.